Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

International Trade Groups Call For Regulators To Protect Off-Patent Industry From Inflation

Generics Players Could Benefit From Greater Control Over Their Prices In 2023

Executive Summary

Rising inflation has exacerbated pressures in the off-patent drug sector, prompting Medicines for Europe and the US Association for Accessible Medicines to call for regulatory intervention to ensure the long-term sustainability of the space.

You may also be interested in...



German Generic Reform To Relax Pediatric Pricing

Germany’s Bundesministerium für Gesundheit is reworking the country’s off-patent drug legislation to allow for more flexible pricing.

Building The Pharma Supply Chain Of The Future

The worst of COVID-19’s disruption appears to be in the pharma supply chain’s rearview mirror, but logistics stakeholders still have a number of questions to answer and challenges to overcome as they attempt to become future-proof.

Commission Publications Highlight Urgency Of Rethinking Investment And Procurement Reform

Medicines for Europe has responded to two recent publications from the European Commission, calling for policy reforms to support the role of generic and biosimilar medicines.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152448

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel